Moreover, patients from whom we derived the organoid cultures used in this study did show an incomplete response to platinum‐based chemotherapy, suggesting that UBE2N inhibition might constitute a promising strategy to overcome resistance to current treatments, which is a major cause of therapeutic failure in ovarian cancer. Here, UBE2N is linked to ovarian cancer.